Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2016 - 2025)

Ultragenyx Pharmaceutical has reported Net Cash Flow over the past 10 years, most recently at $222.1 million for Q4 2025.

  • Quarterly Net Cash Flow rose 749.94% to $222.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $248.0 million through Dec 2025, up 851.52% year-over-year, with the annual reading at $248.0 million for FY2025, 851.52% up from the prior year.
  • Net Cash Flow was $222.1 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $25.8 million in the prior quarter.
  • Over five years, Net Cash Flow peaked at $368.5 million in Q2 2024 and troughed at -$331.3 million in Q3 2024.
  • The 5-year median for Net Cash Flow is -$10.3 million (2022), against an average of -$14.5 million.
  • The largest YoY upside for Net Cash Flow was 2164.18% in 2024 against a maximum downside of 1068.89% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $100.4 million in 2021, then tumbled by 358.92% to -$260.1 million in 2022, then surged by 153.59% to $139.4 million in 2023, then tumbled by 81.25% to $26.1 million in 2024, then surged by 749.94% to $222.1 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Net Cash Flow are $222.1 million (Q4 2025), $25.8 million (Q3 2025), and $46.6 million (Q2 2025).